Trial · NCT00123474
Results by group262
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 262
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up | QD Dasatinib | 51.8 | 95% Confidence Interval 45.4 to 58.2 | percentage of Participants | |
| Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up | BID Dasatinib | 49.0 | 95% Confidence Interval 42.7 to 55.4 | percentage of Participants | |
| Percent of Participants With MCyR At or Prior to 24 Months Follow-Up | Dasatinib QD | 58.3 | 95% Confidence Interval 51.9 to 64.5 | percentage of Participants | |
| Percent of Participants With MCyR At or Prior to 24 Months Follow-Up | Dasatinib BID | 56.4 | 95% Confidence Interval 50.0 to 62.6 | percentage of Participants | |
| Percent of Participants With MCyR At or Prior to 24 Months Follow-Up | Dasatinib 100 mg Total Daily Dose | 57.3 | 95% Confidence Interval 50.8 to 63.5 | percentage of Participants | |
| Percent of Participants With MCyR At or Prior to 24 Months Follow-Up | Dasatinib 140 mg Total Daily Dose | 57.4 | 95% Confidence Interval 51.0 to 63.7 | percentage of Participants | |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 100 mg QD | 6 Months (n=124,123,124,127) | 86.3 | 95% Confidence Interval 79.0 to 91.8 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 140 mg QD | 6 Months (n=124,123,124,127) | 85.4 | 95% Confidence Interval 77.9 to 91.1 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 50 mg BID | 6 Months (n=124,123,124,127) | 91.1 | 95% Confidence Interval 84.7 to 95.5 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 70 mg BID | 6 Months (n=124,123,124,127) | 87.4 | 95% Confidence Interval 80.3 to 92.6 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 100 mg QD | 24 Month (n=124,123,124,126) | 88.7 | 95% Confidence Interval 81.8 to 93.7 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 140 mg QD | 24 Month (n=124,123,124,126) | 86.2 | 95% Confidence Interval 78.8 to 91.7 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 50 mg BID | 24 Month (n=124,123,124,126) | 91.9 | 95% Confidence Interval 85.7 to 96.1 | percentage of participants |
| Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | Dasatinib 70 mg BID | 24 Month (n=124,123,124,126) | 88.9 | 95% Confidence Interval 82.1 to 93.8 | percentage of participants |
| Time to MCyR in Participants With MCyR at 6 Months Follow-Up | Dasatinib 100 mg QD | 2.8 | 95% Confidence Interval 2.8 to 3.0 | Months | |
| Time to MCyR in Participants With MCyR at 6 Months Follow-Up | Dasatinib 140 mg QD | 2.8 | 95% Confidence Interval 2.8 to 2.9 | Months | |
| Time to MCyR in Participants With MCyR at 6 Months Follow-Up | Dasatinib 50 mg BID | 2.8 | 95% Confidence Interval 2.8 to 2.9 | Months | |
| Time to MCyR in Participants With MCyR at 6 Months Follow-Up | Dasatinib 70 mg BID | 2.8 | 95% Confidence Interval 2.8 to 3.0 | Months | |
| Time to CHR in Participants With CHR at 6 Months Follow-Up | Dasatinib 100 mg QD | 0.5 | 95% Confidence Interval 0.5 to 0.6 | Months | |
| Time to CHR in Participants With CHR at 6 Months Follow-Up | Dasatinib 140 mg QD | 0.5 | 95% Confidence Interval 0.5 to 0.7 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00123474/results